89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

February 13, 2018

Conditions

Breast Cancer

Interventions

DRUG

89Zr-Trastuzumab Human Dosimetry and Safety

PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety

DRUG

HER2 Positive Lesion Detection and Safety

Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging

Trial Locations (1)

Washington University School of Medicine @ Barnes-Jewish Hospital, St Louis

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT02065609 - 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography | Biotech Hunter | Biotech Hunter